Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Raj Satkunasivam, MD, MS, FRCSCNon-Muscle Invasive Urothelial Carcinoma | September 8, 2023
Dr. Satkunasivam shares the inspiration for combining sasanlimab with BCG in patients with high-risk, BCG-naïve NMIBC.
View More
Sandip Prasad, MD, MPhilNon-Muscle Invasive Urothelial Carcinoma | August 30, 2023
Dr. Prasad provides overviews of ATLAS and ENVISION and opines on whether UGN-102 is a practice-ready alternative to TURBT.
Leah LawrenceNon-Muscle Invasive Urothelial Carcinoma | August 17, 2023
Several urologists weigh in on BCG, its role in NMIBC treatment, shortages, and strategies to treat BCG-unresponsive disease.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | August 8, 2023
The ATLAS study demonstrated the superiority of UGN-102 over TURBT for patients with low-grade, intermediate-risk NMIBC.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | August 4, 2023
UGN-102 is a sustained-release, hydrogel-based formula that allows bladder tissue to be exposed to mitomycin longer.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | July 10, 2023
Through molecular profiling, three different BCG response subtypes were found: BRS1, BRS2, and BRS3.
Emily MenendezASCO 2023 | June 1, 2023
An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | May 30, 2023
FDA approval of Adstiladrin for use in BCG-unresponsive NMIBC expands the armamentarium for treatment of high-risk NMIBC.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | May 1, 2023
NMIBC-associated costs vary widely across types of treatments utilized, health systems, and regions of the country.
Zachary BessetteAUA 2023: Focus on Bladder Cancer | April 29, 2023
There is significant inter-site variation in recurrence of NMIBC after TRUBT in the RESECT study, according to new research.
Emily MenendezAUA 2023: Focus on Bladder Cancer | April 28, 2023
Study results indicate an alternative strategy to radical cystectomy for comprehensive bladder-preserving therapy for MIBC.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | April 28, 2023
No nonsurgical treatments currently exist for patients with NMIBC who did not respond to BCG therapy.
Emily MenendezAUA 2023: Focus on Bladder Cancer | April 28, 2023
Patients with high-risk NMIBC who underwent TURBT from November 1993 to April 2019 were retrospectively evaluated.
Emily MenendezAUA 2023: Focus on Bladder Cancer | April 28, 2023
A study analyzed effect of time to progression on OS in a cohort of patients with HR-NMIBC treated with intravesical BCG.
David Ambinder, MDNon-Muscle Invasive Urothelial Carcinoma | April 26, 2023
Is there an alternative regimen to BCG for NMIBC? The combination of intravesical gemcitabine and docetaxel may be.
Vignesh Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | March 22, 2023
Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | February 27, 2023
IFNα and nadofaragene firadenovec can provide a new therapy approach for a disease with a significant unmet clinical need.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | February 24, 2023
BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC.
Andrea Necchi, MDASCO GU Symposium 2023 | February 18, 2023
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
Kyle M. Rose, MDASCO GU Symposium 2023 | February 18, 2023
Kyle M. Rose, MD, describes how cell-free DNA is used to detect MRD prior to repeat-transurethral resection in NMIBC.
Advertisement
Advertisement
Advertisement